[go: up one dir, main page]

MA37940B1 - Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses. - Google Patents

Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.

Info

Publication number
MA37940B1
MA37940B1 MA37940A MA37940A MA37940B1 MA 37940 B1 MA37940 B1 MA 37940B1 MA 37940 A MA37940 A MA 37940A MA 37940 A MA37940 A MA 37940A MA 37940 B1 MA37940 B1 MA 37940B1
Authority
MA
Morocco
Prior art keywords
hepatic
useful
nervous system
octahydro
cyclopenta
Prior art date
Application number
MA37940A
Other languages
English (en)
Other versions
MA37940A2 (fr
Inventor
Daniel Hunziker
Patrizio Mattei
Harald Mauser
Jérôme Hert
Guozhi Tang
Lisha Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37940A2 publication Critical patent/MA37940A2/fr
Publication of MA37940B1 publication Critical patent/MA37940B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne de nouveaux composés ayant la formule générale (i) qui sont utiles pour traiter des maladies rénales, troubles hépatiques, inflammatoires, du système nerveux, fibrotiques, le rejet de greffe d'organe aiguë et chronique, système respiratoire, vasculaire et les maladies cardiovasculaires, le cancer, les affections oculaires, troubles métaboliques , prurit cholestatique et chronique
MA37940A 2012-09-25 2013-09-23 Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses. MA37940B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185941 2012-09-25
PCT/EP2013/069679 WO2014048865A1 (fr) 2012-09-25 2013-09-23 Nouveaux dérivés bicycliques

Publications (2)

Publication Number Publication Date
MA37940A2 MA37940A2 (fr) 2016-06-30
MA37940B1 true MA37940B1 (fr) 2018-09-28

Family

ID=47073290

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37940A MA37940B1 (fr) 2012-09-25 2013-09-23 Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.

Country Status (33)

Country Link
US (4) US20150353559A1 (fr)
EP (2) EP3590940B1 (fr)
JP (1) JP6285444B2 (fr)
KR (1) KR102179599B1 (fr)
CN (1) CN104684915B (fr)
AR (1) AR092645A1 (fr)
AU (1) AU2013322838B2 (fr)
BR (1) BR112015004111A2 (fr)
CA (1) CA2878442A1 (fr)
CL (1) CL2015000706A1 (fr)
CR (1) CR20150120A (fr)
DK (1) DK2900669T3 (fr)
EA (1) EA036630B1 (fr)
ES (1) ES2753163T3 (fr)
HK (1) HK1206722A1 (fr)
HR (1) HRP20191937T1 (fr)
HU (1) HUE045797T2 (fr)
IL (1) IL237126A (fr)
IN (1) IN2015DN00960A (fr)
LT (1) LT2900669T (fr)
MA (1) MA37940B1 (fr)
MX (1) MX368615B (fr)
PE (1) PE20150758A1 (fr)
PH (1) PH12015500263B1 (fr)
PL (1) PL2900669T3 (fr)
PT (1) PT2900669T (fr)
RS (1) RS59512B1 (fr)
SG (1) SG11201500572YA (fr)
SI (1) SI2900669T1 (fr)
TW (1) TWI609018B (fr)
UA (1) UA116547C2 (fr)
WO (1) WO2014048865A1 (fr)
ZA (1) ZA201500345B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150023373A (ko) 2012-06-13 2015-03-05 에프. 호프만-라 로슈 아게 신규한 다이아자스피로사이클로알칸 및 아자스피로사이클로알칸
MA37940B1 (fr) 2012-09-25 2018-09-28 Hoffmann La Roche Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
AU2013365742B2 (en) 2012-12-19 2016-11-24 Novartis Ag Autotaxin inhibitors
AR095079A1 (es) * 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105517547A (zh) 2013-07-03 2016-04-20 阿比德治疗公司 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途
EP3461827B1 (fr) 2013-09-26 2022-02-23 Cadent Therapeutics, Inc. Modulateurs de nrb2, à base d'octahydro-cyclopenta[c]pyrrole, à modulation négative sélective
SI3071561T1 (sl) 2013-11-22 2021-11-30 Sabre Therapeutics Llc Spojine, ki inhibirajo avtotaksin
SI3074400T1 (en) * 2013-11-26 2018-03-30 F. Hoffmann-La Roche Ag Octahydro-cyclobut (1,2-c, 3,4-cy) dipyrrole derivatives as autoantaxine inhibitors
MX370659B (es) * 2014-03-26 2019-12-19 Hoffmann La Roche Compuestos bicíclicos como inhibidores de producción de autotaxina (atx) y ácido lisofosfatídico (lpa).
CN106029667B (zh) 2014-03-26 2019-08-23 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1,4]二氮杂*化合物
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AU2016268250B2 (en) 2015-05-27 2020-08-27 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
WO2016197009A1 (fr) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles pour le traitement de maladies liées à la démyélinisation
KR20180043837A (ko) 2015-09-04 2018-04-30 에프. 호프만-라 로슈 아게 페녹시메틸 유도체
JP6846414B2 (ja) * 2015-09-24 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
RU2725138C2 (ru) * 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
RU2724899C2 (ru) * 2015-09-24 2020-06-26 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
JP6876685B2 (ja) * 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
CN106986789B (zh) * 2016-01-20 2019-07-16 中国人民解放军军事医学科学院生物医学分析中心 对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用
WO2017197192A1 (fr) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
WO2018106641A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles pour le traitement de maladies démyélinisantes
WO2018106643A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Azoles hétérocycliques pour le traitement de maladies de démyélinisation
WO2018106646A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles pour traiter des maladies démyélinisantes
WO2018114677A2 (fr) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [(phénylsulfonyl)octahydro-épiminoisoindol-yl](1h-1,2,3-triazol-5-yl)méthanones
WO2018167001A1 (fr) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN110382484B (zh) * 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
EP3448859B1 (fr) 2017-03-20 2019-07-10 Forma Therapeutics, Inc. Compositions de pyrrolopyrrole en tant qu'activateurs de la pyruvate kinase (pkr)
PE20200665A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
EA202090312A1 (ru) 2017-08-29 2020-08-05 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения
JP7301390B2 (ja) 2017-10-19 2023-07-03 ジェイエス・イノファーム・（シャンハイ）・リミテッド ヘテロ環式化合物、ヘテロ環式化合物を含む組成物、及びその使用方法
TWI780281B (zh) * 2017-12-14 2022-10-11 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
EP3853206B1 (fr) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
CN111620866A (zh) * 2019-02-27 2020-09-04 南京药石科技股份有限公司 一种顺式-7,7-二氟-六氢-1H 吡咯并[3,4-c]吡啶衍生物及其制备方法
CN114615977B (zh) 2019-09-19 2025-01-14 诺沃挪第克健康护理股份公司 丙酮酸激酶r(pkr)活化组合物
CN113549063B (zh) * 2020-04-23 2024-04-05 南京药石科技股份有限公司 一种光学异构的八氢-2H-吡咯并[3,4-c]吡啶-2-羧酸叔丁酯的制备方法
TW202211918A (zh) * 2020-06-30 2022-04-01 印度商卡地拉保健有限公司 新穎奧特他新（ａｕｔｏｔａｘｉｎ）抑制劑
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113214111A (zh) * 2021-04-30 2021-08-06 上海立科化学科技有限公司 3-（2-氰基苯基）丙酸及4-氰基-1-茚满酮的制备方法
WO2023107705A1 (fr) 2021-12-10 2023-06-15 Incyte Corporation Amines bicycliques utilisées comme inhibiteurs de cdk12

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1252898B (de) 1965-06-12 1967-10-26 Bayer Ag Verfahren zur Herstellung von Copolymerisaten des Trioxans
US5240928A (en) 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
DE3930262A1 (de) 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA2037630C (fr) 1990-03-07 2001-07-03 Akira Morimoto Composes heterocycliques renfermant de l'azote, methode de production et applications correspondantes
US5470975A (en) 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
US5290780A (en) 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5202322A (en) 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5358951A (en) 1993-04-23 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones
DE4407047A1 (de) * 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
US20010016657A1 (en) * 1997-03-18 2001-08-23 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsants
EP1061076B1 (fr) 1998-02-04 2004-12-08 Banyu Pharmaceutical Co., Ltd. Derives d'amine n-acyle cyclique
JP2001039950A (ja) 1999-07-30 2001-02-13 Banyu Pharmaceut Co Ltd Ｎ−アシル環状アミン誘導体
AU1244001A (en) 1999-10-27 2001-05-08 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
RU2298417C2 (ru) 1999-11-09 2007-05-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
WO2002070523A1 (fr) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulateurs de l'activite du recepteur de la chimiokine
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
WO2005023762A1 (fr) 2003-09-04 2005-03-17 Abbott Laboratories Derives de pyrrolidine-2-carbonitrile et leur utilisation comme inhibiteurs de la dipeptidyle peptidase-iv (dpp-iv)
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP4845873B2 (ja) 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
CN101001860A (zh) * 2004-06-09 2007-07-18 霍夫曼-拉罗奇有限公司 杂环抗病毒化合物
ES2442857T3 (es) 2004-08-10 2014-02-13 Janssen Pharmaceutica Nv Derivados de 1,2,4-triazin-6-ona inhibidores de VIH
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
MX2007013469A (es) 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
US8318931B2 (en) 2005-10-28 2012-11-27 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
EP1960366B1 (fr) * 2005-11-14 2016-07-20 Purdue Research Foundation Indenoisoquinolines n-substituees et leur synthese
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP2008031064A (ja) 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体
WO2008033764A2 (fr) 2006-09-11 2008-03-20 N.V. Organon Dérivés d'acétamide de quinazolinone et d'isoqiinolinone
WO2008033456A1 (fr) 2006-09-15 2008-03-20 Schering Corporation Dérivés d'azétidine spiro-condensés convenant pour le traitement de la douleur, du diabète et des troubles du métabolisme des lipides
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
CA2669884A1 (fr) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Nouveaux 2-(2-hydroxyphenyl)benzimidazoles utilises pour traiter l'obesite et le diabete
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
EP1975165A1 (fr) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrrolidinamide substituée, sa fabrication et son utilisation en tant que médicament
CN101657433A (zh) 2007-03-29 2010-02-24 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
WO2008135141A1 (fr) 2007-04-27 2008-11-13 Sanofi-Aventis Dérivés de 2 -hétéroaryl- pyrrolo [3, 4-c]pyrrole et utilisation comme inhibiteurs de scd
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
JP5808037B2 (ja) 2007-10-19 2015-11-10 サーコード バイオサイエンス インク． 糖尿病性網膜症の治療のための組成物及び方法
PA8802501A1 (es) 2007-10-31 2009-06-23 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno, hidrolasa
JP2009161449A (ja) 2007-12-28 2009-07-23 Lion Corp Ｐｐａｒ活性促進剤並びに美容用飲食品、皮膚外用剤及び医薬
EP2301936A1 (fr) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Dérivé de spirodiamine-diarylcétoxime
WO2010028761A1 (fr) 2008-09-09 2010-03-18 Sanofi-Aventis Dérivés de 2-hétéro-aryl-pyrrolo[3, 4-c]pyrrol et leur utilisation en tant qu'inhibiteurs de scd
TW201020247A (en) 2008-11-06 2010-06-01 Gruenenthal Gmbh Substituierte disulfonamide
US8188090B2 (en) 2008-11-17 2012-05-29 Hoffman-La Roche Inc. Naphthylacetic acids
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
MX2011005720A (es) 2008-12-01 2011-06-17 Merck Patent Gmbh Pirido [4,3-d] pirimidinas 2,5-diamino sustituidas como inhibidores de autotaxina contra cancer.
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
KR20120004483A (ko) * 2009-04-02 2012-01-12 메르크 파텐트 게엠베하 오토탁신 저해제
SG174520A1 (en) * 2009-04-02 2011-10-28 Merck Patent Gmbh Heterocyclic compounds as autotaxin inhibitors
KR20120027177A (ko) 2009-04-02 2012-03-21 메르크 파텐트 게엠베하 오토탁신 저해제로서의 피페리딘 및 피라진 유도체
FR2945534B1 (fr) 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
CA2763099A1 (fr) 2009-05-22 2010-11-25 Exelixis, Inc. Inhibiteurs de pi3k/mtor a base de benzoxazepines pour lutter contre les maladies proliferatives
WO2010141817A1 (fr) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Modulateurs d'amide d'acide gras hydrolase de type diamine urée spirocyclique substituée par un groupe hétéroaryle
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
IN2012DN05233A (fr) * 2010-01-07 2015-10-23 Du Pont
WO2011115813A1 (fr) 2010-03-18 2011-09-22 Abbott Laboratories Acétamides de lactame en tant que bloqueurs des canaux calciques
PT2547679E (pt) 2010-03-19 2016-01-27 Pfizer Derivados de 2,3-di-hidro-1h-indeno-1-il-2,7-diazaspiro[3.6]nonano e sua utilização como antagonistas ou agonistas inversos do receptor de grelina
WO2011116867A1 (fr) 2010-03-26 2011-09-29 Merck Patent Gmbh Benzonaphthyridinamines en tant qu'inhibiteurs d'autotaxine
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
WO2011151461A2 (fr) 2010-06-04 2011-12-08 B.S.R.C. "Alexander Fleming" Modulation de la voie autotaxine et utilisations correspondantes
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
CN103201262B (zh) * 2010-08-20 2016-06-01 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
ES2530345T3 (es) * 2010-09-02 2015-03-02 Merck Patent Gmbh Derivados de pirazolopiridinona como antagonistas del receptor del LPA
EP2651404B1 (fr) 2010-12-14 2015-10-14 Electrophoretics Limited Inhibiteurs de caséine kinase 1 delta (ck1delta)
EP2714680B1 (fr) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Inhibiteurs de l'autotaxine hétérocycliques et leurs utilisations
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
WO2013054185A1 (fr) 2011-10-13 2013-04-18 Pfizer, Inc. Dérivés de pyrimidine et de pyridine utiles en thérapie
JPWO2013065712A1 (ja) 2011-10-31 2015-04-02 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
US8809552B2 (en) 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
CA2856946C (fr) 2011-12-02 2016-08-02 Phenex Pharmaceuticals Ag Pyrrolocarboxamides en tant que modulateurs de l'activite d'un recepteur orphelin gamma (rory, nr1f3) apparente au recepteur nucleaire orphelin rar et destines au traitement de maladies inflammatoires chroniques et auto-immunes
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
KR20150023373A (ko) 2012-06-13 2015-03-05 에프. 호프만-라 로슈 아게 신규한 다이아자스피로사이클로알칸 및 아자스피로사이클로알칸
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
SG11201500342PA (en) 2012-07-27 2015-02-27 Biogen Ma Inc Compounds that are s1p modulating agents and/or atx modulating agents
TWI616430B (zh) 2012-07-27 2018-03-01 百健Ｍａ公司 Ａｔｘ調節劑
MX357035B (es) 2012-09-25 2018-06-25 Bayer Pharma AG Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer.
MA37940B1 (fr) 2012-09-25 2018-09-28 Hoffmann La Roche Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
DK2912019T3 (da) 2012-10-25 2021-05-25 Tetra Discovery Partners Llc Heteroarylhæmmere af pde4
US20160002247A1 (en) 2013-03-01 2016-01-07 The University Of Tokyo 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
US10035800B2 (en) 2013-03-12 2018-07-31 Abbvie Inc. Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
EP2970099A4 (fr) 2013-03-12 2016-12-21 Acucela Inc Dérivés de 3-phénylpropylamine substitués pour le traitement des maladies et des troubles ophtalmiques
EP2970302A1 (fr) 2013-03-15 2016-01-20 Biogen MA Inc. Modulateurs de s1p et/ou de l'atx
SG11201600241RA (en) 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
PT3057959T (pt) 2013-10-17 2018-06-04 Vertex Pharma Inibidores de adn-pk
SI3071561T1 (sl) 2013-11-22 2021-11-30 Sabre Therapeutics Llc Spojine, ki inhibirajo avtotaksin
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
SI3074400T1 (en) 2013-11-26 2018-03-30 F. Hoffmann-La Roche Ag Octahydro-cyclobut (1,2-c, 3,4-cy) dipyrrole derivatives as autoantaxine inhibitors
CN106132935A (zh) 2014-03-26 2016-11-16 巴斯夫欧洲公司 作为杀真菌剂的取代的[1,2,4]三唑和咪唑化合物
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX370659B (es) 2014-03-26 2019-12-19 Hoffmann La Roche Compuestos bicíclicos como inhibidores de producción de autotaxina (atx) y ácido lisofosfatídico (lpa).
CN106029667B (zh) 2014-03-26 2019-08-23 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1,4]二氮杂*化合物
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
UA118989C2 (uk) 2014-10-14 2019-04-10 Вітае Фармасьютікалс, Інк. Дигідропіролопіридинові інгібітори ror-гамма
PE20180177A1 (es) 2015-02-15 2018-01-22 Hoffmann La Roche Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN104927727B (zh) 2015-07-06 2017-01-11 香山红叶建设有限公司 一种玻璃幕墙用结构密封胶及其制备方法
KR20180043837A (ko) 2015-09-04 2018-04-30 에프. 호프만-라 로슈 아게 페녹시메틸 유도체
PL415078A1 (pl) 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
RU2724899C2 (ru) 2015-09-24 2020-06-26 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
RU2725138C2 (ru) 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
WO2017053722A1 (fr) 2015-09-24 2017-03-30 Ionis Pharmaceuticals, Inc. Modulateurs de l'expression de kras
JP6846414B2 (ja) 2015-09-24 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
SG11201803210YA (en) 2015-11-25 2018-05-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
CN108290858B (zh) 2015-12-01 2021-07-06 日本农药株式会社 3h-吡咯并吡啶化合物或其n-氧化物、或它们的盐类及含有该化合物的农业园艺用杀虫剂及其使用方法
WO2017139978A1 (fr) 2016-02-19 2017-08-24 吴伟东 Procédé et système d'actualisation d'application de téléphone mobile
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
WO2018167001A1 (fr) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
EP3448859B1 (fr) 2017-03-20 2019-07-10 Forma Therapeutics, Inc. Compositions de pyrrolopyrrole en tant qu'activateurs de la pyruvate kinase (pkr)

Also Published As

Publication number Publication date
KR102179599B1 (ko) 2020-11-19
TWI609018B (zh) 2017-12-21
EP2900669B1 (fr) 2019-09-04
MX368615B (es) 2019-10-09
BR112015004111A2 (pt) 2017-07-04
MX2015002090A (es) 2015-05-11
US10669268B2 (en) 2020-06-02
PH12015500263B1 (en) 2022-06-17
EP2900669A1 (fr) 2015-08-05
CN104684915B (zh) 2017-10-31
TW201422618A (zh) 2014-06-16
US20180118741A1 (en) 2018-05-03
LT2900669T (lt) 2019-11-11
KR20150060713A (ko) 2015-06-03
IL237126A (en) 2016-12-29
IN2015DN00960A (fr) 2015-06-12
CR20150120A (es) 2015-04-14
WO2014048865A1 (fr) 2014-04-03
HRP20191937T1 (hr) 2020-01-10
US20200339570A1 (en) 2020-10-29
HK1206722A1 (en) 2016-01-15
AU2013322838A1 (en) 2015-01-29
ES2753163T3 (es) 2020-04-07
PE20150758A1 (es) 2015-05-15
JP6285444B2 (ja) 2018-02-28
AR092645A1 (es) 2015-04-29
MA37940A2 (fr) 2016-06-30
PT2900669T (pt) 2019-10-29
EA036630B1 (ru) 2020-12-02
HUE045797T2 (hu) 2020-01-28
AU2013322838B2 (en) 2018-02-01
CN104684915A (zh) 2015-06-03
UA116547C2 (uk) 2018-04-10
ZA201500345B (en) 2015-12-23
PH12015500263A1 (en) 2015-03-30
EP3590940B1 (fr) 2021-06-09
EP3590940A1 (fr) 2020-01-08
PL2900669T3 (pl) 2020-01-31
DK2900669T3 (da) 2019-11-04
EA201590534A1 (ru) 2015-07-30
CA2878442A1 (fr) 2014-04-03
RS59512B1 (sr) 2019-12-31
JP2015531360A (ja) 2015-11-02
CL2015000706A1 (es) 2015-08-07
US20170050960A1 (en) 2017-02-23
US20150353559A1 (en) 2015-12-10
SG11201500572YA (en) 2015-02-27
SI2900669T1 (sl) 2019-12-31

Similar Documents

Publication Publication Date Title
MA37940B1 (fr) Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
EA201990045A1 (ru) Новое соединение в качестве ингибитора аутотоксина и содержащая его фармацевтическая композиция
MX373236B (es) Compuestos condensados de [1,4]diazepina como inhibidores de producción de la autotaxina (atx) y ácido lisofosfatidico (lpa).
PH12016501835A1 (en) 5-substituted indazole -3- carboxamides and preparation and use thereof
MA39792B1 (fr) Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
EA201591689A1 (ru) НОВЫЕ N-АЦИЛ-(3-ЗАМЕЩЕННЫЕ)-(8-ЗАМЕЩЕННЫЕ)-5,6-ДИГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И МЕТОДЫ ИСПОЛЬЗОВАНИЯ ПРИ РАССТРОЙСТВАХ,ОПОСРЕДОВАННЫХ РЕЦЕПТОРОМ NK-3
MY184882A (en) Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors
MA34284B1 (fr) Indoles
MA34235B1 (fr) Composes chimiques
EP2773779A4 (fr) Méthodes et compositions pour le diagnostic, le pronostic et le traitement d'états neurologiques
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
UA116774C2 (uk) Інгібітори серин/треонінкінази
EA201391290A1 (ru) Гетероциклические модуляторы синтеза липидов
EA201590624A1 (ru) Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
UA112795C2 (uk) Біциклічні піразинонові похідні
EP2935594A4 (fr) Procédés d'augmentation de la teneur en matières grasses/huile de plantes
EA201691141A1 (ru) Соединения против ccr6
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
EA201400879A1 (ru) Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EP2782566A4 (fr) Compositions de l-sérine, méthodes et utilisations pour le traitement de maladies et de troubles neurodégénératifs
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение